Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQT NASDAQ:DYN NASDAQ:GPCR NASDAQ:JBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$26.21$22.77$13.06▼$31.77$3.28B1.511.70 million shs5.48 million shsDYNDyne Therapeutics$19.80$18.33$8.06▼$25.00$3.27B1.091.72 million shs5.11 million shsGPCRStructure Therapeutics$44.51$42.71$15.80▼$94.90$3.16B-1.35731,717 shs1.15 million shsJBIOJade Biosciences$16.82$21.02$6.67▼$28.00$830.23M1.441.39 million shs4.79 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics0.00%+7.51%+28.04%+18.06%+91.73%DYNDyne Therapeutics0.00%+8.85%+12.76%+12.76%+83.67%GPCRStructure Therapeutics0.00%+3.68%+20.72%-8.24%+105.87%JBIOJade Biosciences0.00%+9.65%-27.93%+20.14%+78.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$26.21$22.77$13.06▼$31.77$3.28B1.511.70 million shs5.48 million shsDYNDyne Therapeutics$19.80$18.33$8.06▼$25.00$3.27B1.091.72 million shs5.11 million shsGPCRStructure Therapeutics$44.51$42.71$15.80▼$94.90$3.16B-1.35731,717 shs1.15 million shsJBIOJade Biosciences$16.82$21.02$6.67▼$28.00$830.23M1.441.39 million shs4.79 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics0.00%+7.51%+28.04%+18.06%+91.73%DYNDyne Therapeutics0.00%+8.85%+12.76%+12.76%+83.67%GPCRStructure Therapeutics0.00%+3.68%+20.72%-8.24%+105.87%JBIOJade Biosciences0.00%+9.65%-27.93%+20.14%+78.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics 2.50Moderate Buy$34.0029.72% UpsideDYNDyne Therapeutics 2.93Moderate Buy$33.8570.94% UpsideGPCRStructure Therapeutics 2.89Moderate Buy$106.75139.83% UpsideJBIOJade Biosciences 2.90Moderate Buy$47.13180.17% UpsideCurrent Analyst Ratings BreakdownLatest JBIO, ARQT, DYN, and GPCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026JBIOJade Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)6/15/2026JBIOJade Biosciences UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.006/15/2026JBIOJade Biosciences UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.006/11/2026GPCRStructure Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$100.00 ➝ $70.006/2/2026JBIOJade Biosciences Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$55.006/2/2026JBIOJade Biosciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.006/2/2026JBIOJade Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$34.00 ➝ $45.006/1/2026JBIOJade Biosciences Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/1/2026JBIOJade Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)6/1/2026JBIOJade Biosciences BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$39.00 ➝ $74.006/1/2026JBIOJade Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$45.00 ➝ $55.00(Data available from 6/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$415.62M7.89N/AN/A$1.55 per share16.91DYNDyne TherapeuticsN/AN/AN/AN/A$6.81 per shareN/AGPCRStructure TherapeuticsN/AN/AN/AN/A$24.99 per shareN/AJBIOJade BiosciencesN/AN/AN/AN/A$6.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$16.14M-$0.03N/A27.30N/A-0.57%-1.41%-0.59%8/5/2026 (Estimated)DYNDyne Therapeutics-$446.21M-$3.22N/AN/AN/AN/A-58.28%-46.77%7/27/2026 (Estimated)GPCRStructure Therapeutics-$141.20M-$0.87N/AN/AN/AN/A-24.91%-23.67%8/6/2026 (Estimated)JBIOJade Biosciences-$127.41M-$2.02N/AN/AN/AN/A-51.34%-47.32%N/ALatest JBIO, ARQT, DYN, and GPCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026DYNDyne Therapeutics-$0.7723-$0.73+$0.0423-$0.73N/AN/A5/7/2026Q1 2026GPCRStructure Therapeutics-$0.39-$0.35+$0.04-$0.35$11.11 millionN/A5/7/2026Q1 2026JBIOJade Biosciences-$0.52-$0.57-$0.05-$0.57N/AN/A5/6/2026Q1 2026ARQTArcutis Biotherapeutics-$0.02-$0.09-$0.07-$0.09$103.68 million$105.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/AJBIOJade BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics0.542.682.46DYNDyne Therapeutics0.1719.9219.92GPCRStructure TherapeuticsN/A26.1626.16JBIOJade BiosciencesN/A14.2914.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/ADYNDyne Therapeutics96.68%GPCRStructure Therapeutics91.78%JBIOJade BiosciencesN/AInsider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics9.40%DYNDyne Therapeutics9.46%GPCRStructure Therapeutics5.50%JBIOJade Biosciences23.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics150125.08 million113.33 millionOptionableDYNDyne Therapeutics100165.31 million149.68 millionOptionableGPCRStructure Therapeutics13671.07 million67.17 millionOptionableJBIOJade Biosciences2049.36 million37.98 millionN/AJBIO, ARQT, DYN, and GPCR HeadlinesRecent News About These CompaniesJade Biosciences, Inc. (NASDAQ:JBIO) Receives Average Rating of "Moderate Buy" from BrokeragesJune 16, 2026 | americanbankingnews.comJade Biosciences Shareholders Approve Governance and Audit MeasuresJune 11, 2026 | tipranks.comJade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesJune 5, 2026 | markets.businessinsider.comJade Biosciences Completes Public Offering of 11.5 Million Shares, Raising $172.5 Million for Autoimmune Disease TherapiesJune 5, 2026 | quiverquant.comQJade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesJune 5, 2026 | globenewswire.comJade Biosciences prices $150M public offering of common stock at $15/shareJune 4, 2026 | msn.comJade Biosciences Launches Major Underwritten Equity OfferingJune 4, 2026 | tipranks.comJADE101 Phase 1 Trial Marks Key Early Milestone for Jade Biosciences InvestorsJune 4, 2026 | tipranks.comJade Biosciences Announces Pricing of Public Offering of Common StockJune 3, 2026 | globenewswire.comJade Biosciences plans public offering, pre-funded warrantsJune 3, 2026 | msn.comJade Biosciences, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded WarrantsJune 3, 2026 | quiverquant.comQJade Biosciences Announces Proposed Underwritten Public OfferingJune 3, 2026 | globenewswire.comJade Biosciences, Inc. (JBIO)June 2, 2026 | finance.yahoo.comJade Biosciences' JADE101 delivers deep IgA cuts, clearing path for kidney trialsJune 2, 2026 | msn.comJade Biosciences: Strong Early Signal, But Still A Wait For ProofJune 2, 2026 | seekingalpha.comJade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney TrialsJune 1, 2026 | marketbeat.comJade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans TranscriptJune 1, 2026 | seekingalpha.comWhy Is Jade Biosciences Stock Trading Lower On Monday?June 1, 2026 | benzinga.comJade Biosciences Reports Promising Phase 1 Trial Results for JADE101, Demonstrating Sustained IgA Reductions and Favorable Tolerability in Healthy VolunteersJune 1, 2026 | quiverquant.comQJade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA NephropathyJune 1, 2026 | globenewswire.comJade Biosciences to Host Conference Call on Phase 1 Study Results of JADE101 for Immunoglobulin A NephropathyMay 29, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJBIO, ARQT, DYN, and GPCR Company DescriptionsArcutis Biotherapeutics NASDAQ:ARQT$26.21 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$26.71 +0.50 (+1.90%) As of 06/18/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Dyne Therapeutics NASDAQ:DYN$19.80 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$19.98 +0.18 (+0.93%) As of 06/18/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Structure Therapeutics NASDAQ:GPCR$44.51 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$44.31 -0.20 (-0.45%) As of 06/18/2026 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Jade Biosciences NASDAQ:JBIO$16.82 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$16.90 +0.07 (+0.45%) As of 06/18/2026 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
